# Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer

> **NCT03846128** · — · TERMINATED · sponsor: **University Hospital, Rouen** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Kidney Cancer

## Interventions

- **BIOLOGICAL:** blood sample

## Key facts

- **NCT ID:** NCT03846128
- **Lead sponsor:** University Hospital, Rouen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-03
- **Primary completion:** 2021-10-08
- **Final completion:** 2021-10-08
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Changes in the indication for Sunitinib in metastatic renal cell carcinoma, which have led to a significant decrease in its use in the urology department. Collected data will not be sufficient to perform a statistical analysis.
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03846128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03846128, "Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03846128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*